Quellis Biosciences is a biotechnology startup founded in 2017 with a mission to improve the lives of patients with rare diseases through advanced antibody therapies. The company is focused on developing superior treatments for underserved patients in the Biotechnology, Health Care, and Pharmaceutical industries. Its commitment to enhancing patient lives is reflected in its slogan, "Committed to enhancing patient lives with advanced antibody treatments for rare diseases."
Quellis Biosciences recently secured a significant $17.00M Series A investment on 10 December 2019, with participation from prominent investors such as Perceptive Advisors and Viridian Biosciences. This investment signifies a strong show of support for the company's vision and potential in the biopharmaceutical space.
